Home / About Us

YUHAN USA

Yuhan USA serves as Yuhan Corporation’s global business development arm, pursuing strategic collaboration and partnerships with academic research institutions, biotechnology companies, and pharmaceutical companies worldwide. Our activities focus on advancing out-licensing opportunities for Yuhan’s oncology and non-oncology assets, while identifying therapeutic assets with validated proof-of-concept data for potential equity investment and in-licensing.

Our R&D Focus Areas

Our Investment Focus

Lead• Biotech• Academia• Institute• Global PharmaYuhan’s Core CapabilityClinical-Preclinical Translational ResearchCandidatePreclinicalPoC / CMCPhase Ⅰ,ⅡPhase Ⅲ, Ⅳ• Biotech• Academia• Institute• Global PharmaYuhan’s Core CapabilityPreclinical-Clinial Translational ResearchLeadCandidatePoC/CMCPreclinicalPhaseⅠ,ⅡPhaseⅢ, ⅣPreclinicalP1P2P3MarketedLazertinibYH32367YH42946YH32364YH45057YH44529YH25724YH33619YH35324YH359953rd-gen EGFR TKIHERS/4-1BB, bsAbHERS2 TKI, NCEEGFR/4-1BB, bsAbAR TPDSOS1 inhibitorFGF21/GLP1 fusion proteinUndisclosed, NCEIgE trapGCS inhibitorOncologyImmunologyMetabolism &FibrosisFDA, EMALazertinibYH32367YH42946YH32364YH45057YH44529YH25724YH33619YH35324YH359953rd-gen EGFR TKIHER2/4-1BB, bsAbHER2 TKI, NCEEGFR/4-1BB, bsAbAR TPDSOS1 inhibitorFGF21/GLP1 fusion proteinUndisclosed, NCEIgE trapGCS inhibitorOncologyImmunologyMetabolism &FibrosisPreclinicalP1P2P3MarketedFDA, EMALorem ipsumOncology• Targeted therapy• Immuno-oncology• Targeted protein degradationPlatform Technology• Next-gen. antibody technology (ADC, DAC, etc.)• Next-gen. oral delivery (oral delivery of biologics, sustained delivery of small chemicals, etc.)Immunology &Inflammation• Autoimmune disease• Inflammatory disease• RNA TherapeuticsCardiovascular, Renal &Metabolism• Metabolic disease (MASH, Obesity)• Tissue fibrosis

Therapeutics and technology that transforms care for patients in the U.S. and global markets.

Lead• Biotech• Academia• Institute• Global PharmaYuhan’s Core CapabilityClinical-Preclinical Translational ResearchCandidatePreclinicalPoC / CMCPhase Ⅰ,ⅡPhase Ⅲ, Ⅳ• Biotech• Academia• Institute• Global PharmaYuhan’s Core CapabilityPreclinical-Clinial Translational ResearchLeadCandidatePoC/CMCPreclinicalPhaseⅠ,ⅡPhaseⅢ, ⅣPreclinicalP1P2P3MarketedLazertinibYH32367YH42946YH32364YH45057YH44529YH25724YH33619YH35324YH359953rd-gen EGFR TKIHERS/4-1BB, bsAbHERS2 TKI, NCEEGFR/4-1BB, bsAbAR TPDSOS1 inhibitorFGF21/GLP1 fusion proteinUndisclosed, NCEIgE trapGCS inhibitorOncologyImmunologyMetabolism &FibrosisFDA, EMALazertinibYH32367YH42946YH32364YH45057YH44529YH25724YH33619YH35324YH359953rd-gen EGFR TKIHER2/4-1BB, bsAbHER2 TKI, NCEEGFR/4-1BB, bsAbAR TPDSOS1 inhibitorFGF21/GLP1 fusion proteinUndisclosed, NCEIgE trapGCS inhibitorOncologyImmunologyMetabolism &FibrosisPreclinicalP1P2P3MarketedFDA, EMALorem ipsumOncology• Targeted therapy• Immuno-oncology• Targeted protein degradationPlatform Technology• Next-gen. antibody technology (ADC, DAC, etc.)• Next-gen. oral delivery (oral delivery of biologics, sustained delivery of small chemicals, etc.)Immunology &Inflammation• Autoimmune disease• Inflammatory disease• RNA TherapeuticsCardiovascular, Renal &Metabolism• Metabolic disease (MASH, Obesity)• Tissue fibrosis

Strong management teams that are able to focus on the bigger picture and efficiently utilize capital by strategically prioritizing assets for optimal long-term value creation.​

Lead• Biotech• Academia• Institute• Global PharmaYuhan’s Core CapabilityClinical-Preclinical Translational ResearchCandidatePreclinicalPoC / CMCPhase Ⅰ,ⅡPhase Ⅲ, Ⅳ• Biotech• Academia• Institute• Global PharmaYuhan’s Core CapabilityPreclinical-Clinial Translational ResearchLeadCandidatePoC/CMCPreclinicalPhaseⅠ,ⅡPhaseⅢ, ⅣPreclinicalP1P2P3MarketedLazertinibYH32367YH42946YH32364YH45057YH44529YH25724YH33619YH35324YH359953rd-gen EGFR TKIHERS/4-1BB, bsAbHERS2 TKI, NCEEGFR/4-1BB, bsAbAR TPDSOS1 inhibitorFGF21/GLP1 fusion proteinUndisclosed, NCEIgE trapGCS inhibitorOncologyImmunologyMetabolism &FibrosisFDA, EMALazertinibYH32367YH42946YH32364YH45057YH44529YH25724YH33619YH35324YH359953rd-gen EGFR TKIHER2/4-1BB, bsAbHER2 TKI, NCEEGFR/4-1BB, bsAbAR TPDSOS1 inhibitorFGF21/GLP1 fusion proteinUndisclosed, NCEIgE trapGCS inhibitorOncologyImmunologyMetabolism &FibrosisPreclinicalP1P2P3MarketedFDA, EMALorem ipsumOncology• Targeted therapy• Immuno-oncology• Targeted protein degradationPlatform Technology• Next-gen. antibody technology (ADC, DAC, etc.)• Next-gen. oral delivery (oral delivery of biologics, sustained delivery of small chemicals, etc.)Immunology &Inflammation• Autoimmune disease• Inflammatory disease• RNA TherapeuticsCardiovascular, Renal &Metabolism• Metabolic disease (MASH, Obesity)• Tissue fibrosis

Potential for partnerships and collaborations with global pharmaceutical companies, including those in our South Korean network​

YUHAN Corporation

Since 1926, Yuhan Corporation has upheld its commitment to transparent management and extensive research, striving to develop innovative drugs that positively impact people. With over 300 scientists at Yuhan Research Institute, we are striving to become a patient-centered global leading pharmaceutical company.